Gene Therapy is fastest growing segment fueling the growth of Drug and Gene Delivery Devices Market
The global Drug and Gene Delivery Devices Market is estimated to be valued at US$ 169.3 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Drug and gene delivery devices play a vital role in effective
administration of pharmaceutical and biotech products. These devices help in
safe and targeted delivery of drugs, proteins, vaccines and genes into the body
through various routes of administration including oral, pulmonary,
intravenous, intradermal and others.
Market key trends:
One of the key trends driving the growth of drug
and gene delivery devices market size is the increasing adoption of
advanced drug delivery systems. Advanced drug delivery systems help in
overcoming challenges associated with conventional drug delivery methods such
as short half-life, multiple dosing and side effects. These systems offer
controlled, targeted and sustained drug release leading to better patient
compliance and treatment outcomes. Attributes like controlled drug release,
minimal toxicity and targeted drug delivery have increased preference for
advanced drug delivery systems globally.
Segment Analysis
The global Drug and Gene Delivery Devices market is
segmented into viral and non-viral delivery systems. The viral delivery systems
segment dominates the market owing to the high transduction and transfection
efficiency offered by viral vectors in delivering therapeutic genes inside the
target cells. Lentivirus and adenovirus are the commonly used viral vectors for
therapeutic gene delivery.
Key Takeaways
The global Drug and Gene Delivery Devices market is expected to witness
high growth, exhibiting a CAGR of 11% over the forecast period, due to
increasing prevalence of cancers and rising demand for advanced treatment
options.
Regional analysis
North America dominates the global Drug and Gene Delivery Devices market
owing to the presence of major players, advanced healthcare infrastructure, and
rising research funding for drug and gene therapies in the US and Canada. Asia
Pacific is expected to exhibit the fastest growth over the forecast period due
to increasing healthcare expenditure and expanding healthcare facilities in
developing countries such as China and India.
Key players
Key players operating in the Drug and Gene Delivery Devices market are
Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton
Dickinson and Company, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark
Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue
Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Helixmith Co.,
Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek
Biosciences, Inc (Fibrocell Technologies, Inc.), among others. These players
are focusing on new product launches and collaborations to strengthen their
market position.
Get
more insights on this topic: https://www.newsstatix.com/drug-and-gene-delivery-devices-market-share-and-opportunity-analysis-2023-2030/
Comments
Post a Comment